The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection
The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown. Nineteen patients with chronic HBV/HCV co-infection (HBsAg and HCV-RNA positive; 10 HCV-genotype 1; 9 HCV-genotype 2 or 3) were included in this prospective multicenter pilot study. Baseline HBV-DNA...
Gespeichert in:
Veröffentlicht in: | Journal of hepatology 2008-11, Vol.49 (5), p.688 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 5 |
container_start_page | 688 |
container_title | Journal of hepatology |
container_volume | 49 |
creator | Potthoff, Andrej Wedemeyer, Heiner Boecher, Wulf O Berg, Thomas Zeuzem, Stefan Arnold, Joachim Spengler, Ulrich Gruengreiff, Kurt Kaeser, Thomas Schuchmann, Marcus Bergk, Alexandra Forestier, Nicole Deterding, Katja Manns, Michael P Trautwein, Christian |
description | The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown.
Nineteen patients with chronic HBV/HCV co-infection (HBsAg and HCV-RNA positive; 10 HCV-genotype 1; 9 HCV-genotype 2 or 3) were included in this prospective multicenter pilot study. Baseline HBV-DNA was negative in 13 individuals. All patients received weight-adjusted PEG-IFN-alpha2b and ribavirin for 48 weeks.
In the intent-to-treat analysis, a biochemical and an HCV-RNA response were observed in 12 and 14 patients, respectively (63% and 74%). At the end of the treatment as well as at the end of the follow-up the HCV-RNA response was 93% (14/15) in patients adherent to therapy (86% in genotype 1 and 100% in genotypes 2 and 3 infection). Two of the five initially HBV-DNA positive patients with follow-up available were HBV-DNA negative at follow-up week 24. In contrast, HBV-DNA became detectable after the clearance of HCV in four initially HBV-DNA negative patients.
Combination therapy with PEG-IFN-a2b and ribavirin is highly effective in inducing a virological response concerning HCV in patients with HBV/HCV co-infection. However, HBV replication may increase after the clearance of HCV and thus close monitoring for both the viruses is recommended even in patients with initially undetectable HBV-DNA. |
doi_str_mv | 10.1016/j.jhep.2008.03.028 |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_18490077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18490077</sourcerecordid><originalsourceid>FETCH-LOGICAL-p547-a091ffd56b269471f5250221038c17be12b5eb3fa4d0f92dd6362229e104a31a3</originalsourceid><addsrcrecordid>eNpVkEtOwzAQhr0A0VK4AAs0F0g6dt7s2qgQJAQsom4rJ7YbV2liOW5RzsUFCQIWrEb6H59GPyF3FH2KNF4e_EMjjc8QUx8DH1l6QeaTkXopS9IZuR6GAyIGmIVXZEbTMENMkjn5LBsJxebde92UsF7mUPee7pSsne47cFbz9gFWYGw_mG_xLOF4ap2uZeekhcGdxAiuB92d5eD0njsJbkJKpXTN6xF6BUbux3YyxJSaSkravvN4axrOKuCdAKsrftZWd1MADHd6gg_woV0DxXq7LPLtv7duyKXi7SBvf--ClI-bMi-8l7en53z14pkoTDyOGVVKRHHF4ixMqIpYhIxRDNKaJpWkrIpkFSgeClQZEyIOYsZYJimGPKA8WJD7H6w5VUcpdsbqI7fj7m-84AtVUnJi</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Potthoff, Andrej ; Wedemeyer, Heiner ; Boecher, Wulf O ; Berg, Thomas ; Zeuzem, Stefan ; Arnold, Joachim ; Spengler, Ulrich ; Gruengreiff, Kurt ; Kaeser, Thomas ; Schuchmann, Marcus ; Bergk, Alexandra ; Forestier, Nicole ; Deterding, Katja ; Manns, Michael P ; Trautwein, Christian</creator><creatorcontrib>Potthoff, Andrej ; Wedemeyer, Heiner ; Boecher, Wulf O ; Berg, Thomas ; Zeuzem, Stefan ; Arnold, Joachim ; Spengler, Ulrich ; Gruengreiff, Kurt ; Kaeser, Thomas ; Schuchmann, Marcus ; Bergk, Alexandra ; Forestier, Nicole ; Deterding, Katja ; Manns, Michael P ; Trautwein, Christian ; Hep-Net B/C Co-infection Study Group</creatorcontrib><description>The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown.
Nineteen patients with chronic HBV/HCV co-infection (HBsAg and HCV-RNA positive; 10 HCV-genotype 1; 9 HCV-genotype 2 or 3) were included in this prospective multicenter pilot study. Baseline HBV-DNA was negative in 13 individuals. All patients received weight-adjusted PEG-IFN-alpha2b and ribavirin for 48 weeks.
In the intent-to-treat analysis, a biochemical and an HCV-RNA response were observed in 12 and 14 patients, respectively (63% and 74%). At the end of the treatment as well as at the end of the follow-up the HCV-RNA response was 93% (14/15) in patients adherent to therapy (86% in genotype 1 and 100% in genotypes 2 and 3 infection). Two of the five initially HBV-DNA positive patients with follow-up available were HBV-DNA negative at follow-up week 24. In contrast, HBV-DNA became detectable after the clearance of HCV in four initially HBV-DNA negative patients.
Combination therapy with PEG-IFN-a2b and ribavirin is highly effective in inducing a virological response concerning HCV in patients with HBV/HCV co-infection. However, HBV replication may increase after the clearance of HCV and thus close monitoring for both the viruses is recommended even in patients with initially undetectable HBV-DNA.</description><identifier>ISSN: 0168-8278</identifier><identifier>DOI: 10.1016/j.jhep.2008.03.028</identifier><identifier>PMID: 18490077</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Adult ; Aged ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; DNA, Viral - blood ; Female ; Hepatitis B, Chronic - complications ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - virology ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; Humans ; Interferon-alpha - administration & dosage ; Interferon-alpha - adverse effects ; Male ; Middle Aged ; Polyethylene Glycols ; Prospective Studies ; Recombinant Proteins ; Ribavirin - administration & dosage ; Ribavirin - adverse effects ; RNA, Viral - blood</subject><ispartof>Journal of hepatology, 2008-11, Vol.49 (5), p.688</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18490077$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Potthoff, Andrej</creatorcontrib><creatorcontrib>Wedemeyer, Heiner</creatorcontrib><creatorcontrib>Boecher, Wulf O</creatorcontrib><creatorcontrib>Berg, Thomas</creatorcontrib><creatorcontrib>Zeuzem, Stefan</creatorcontrib><creatorcontrib>Arnold, Joachim</creatorcontrib><creatorcontrib>Spengler, Ulrich</creatorcontrib><creatorcontrib>Gruengreiff, Kurt</creatorcontrib><creatorcontrib>Kaeser, Thomas</creatorcontrib><creatorcontrib>Schuchmann, Marcus</creatorcontrib><creatorcontrib>Bergk, Alexandra</creatorcontrib><creatorcontrib>Forestier, Nicole</creatorcontrib><creatorcontrib>Deterding, Katja</creatorcontrib><creatorcontrib>Manns, Michael P</creatorcontrib><creatorcontrib>Trautwein, Christian</creatorcontrib><creatorcontrib>Hep-Net B/C Co-infection Study Group</creatorcontrib><title>The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown.
Nineteen patients with chronic HBV/HCV co-infection (HBsAg and HCV-RNA positive; 10 HCV-genotype 1; 9 HCV-genotype 2 or 3) were included in this prospective multicenter pilot study. Baseline HBV-DNA was negative in 13 individuals. All patients received weight-adjusted PEG-IFN-alpha2b and ribavirin for 48 weeks.
In the intent-to-treat analysis, a biochemical and an HCV-RNA response were observed in 12 and 14 patients, respectively (63% and 74%). At the end of the treatment as well as at the end of the follow-up the HCV-RNA response was 93% (14/15) in patients adherent to therapy (86% in genotype 1 and 100% in genotypes 2 and 3 infection). Two of the five initially HBV-DNA positive patients with follow-up available were HBV-DNA negative at follow-up week 24. In contrast, HBV-DNA became detectable after the clearance of HCV in four initially HBV-DNA negative patients.
Combination therapy with PEG-IFN-a2b and ribavirin is highly effective in inducing a virological response concerning HCV in patients with HBV/HCV co-infection. However, HBV replication may increase after the clearance of HCV and thus close monitoring for both the viruses is recommended even in patients with initially undetectable HBV-DNA.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - adverse effects</subject><subject>DNA, Viral - blood</subject><subject>Female</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - virology</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Polyethylene Glycols</subject><subject>Prospective Studies</subject><subject>Recombinant Proteins</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribavirin - adverse effects</subject><subject>RNA, Viral - blood</subject><issn>0168-8278</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkEtOwzAQhr0A0VK4AAs0F0g6dt7s2qgQJAQsom4rJ7YbV2liOW5RzsUFCQIWrEb6H59GPyF3FH2KNF4e_EMjjc8QUx8DH1l6QeaTkXopS9IZuR6GAyIGmIVXZEbTMENMkjn5LBsJxebde92UsF7mUPee7pSsne47cFbz9gFWYGw_mG_xLOF4ap2uZeekhcGdxAiuB92d5eD0njsJbkJKpXTN6xF6BUbux3YyxJSaSkravvN4axrOKuCdAKsrftZWd1MADHd6gg_woV0DxXq7LPLtv7duyKXi7SBvf--ClI-bMi-8l7en53z14pkoTDyOGVVKRHHF4ixMqIpYhIxRDNKaJpWkrIpkFSgeClQZEyIOYsZYJimGPKA8WJD7H6w5VUcpdsbqI7fj7m-84AtVUnJi</recordid><startdate>200811</startdate><enddate>200811</enddate><creator>Potthoff, Andrej</creator><creator>Wedemeyer, Heiner</creator><creator>Boecher, Wulf O</creator><creator>Berg, Thomas</creator><creator>Zeuzem, Stefan</creator><creator>Arnold, Joachim</creator><creator>Spengler, Ulrich</creator><creator>Gruengreiff, Kurt</creator><creator>Kaeser, Thomas</creator><creator>Schuchmann, Marcus</creator><creator>Bergk, Alexandra</creator><creator>Forestier, Nicole</creator><creator>Deterding, Katja</creator><creator>Manns, Michael P</creator><creator>Trautwein, Christian</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200811</creationdate><title>The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection</title><author>Potthoff, Andrej ; Wedemeyer, Heiner ; Boecher, Wulf O ; Berg, Thomas ; Zeuzem, Stefan ; Arnold, Joachim ; Spengler, Ulrich ; Gruengreiff, Kurt ; Kaeser, Thomas ; Schuchmann, Marcus ; Bergk, Alexandra ; Forestier, Nicole ; Deterding, Katja ; Manns, Michael P ; Trautwein, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p547-a091ffd56b269471f5250221038c17be12b5eb3fa4d0f92dd6362229e104a31a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - adverse effects</topic><topic>DNA, Viral - blood</topic><topic>Female</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - virology</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Polyethylene Glycols</topic><topic>Prospective Studies</topic><topic>Recombinant Proteins</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribavirin - adverse effects</topic><topic>RNA, Viral - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Potthoff, Andrej</creatorcontrib><creatorcontrib>Wedemeyer, Heiner</creatorcontrib><creatorcontrib>Boecher, Wulf O</creatorcontrib><creatorcontrib>Berg, Thomas</creatorcontrib><creatorcontrib>Zeuzem, Stefan</creatorcontrib><creatorcontrib>Arnold, Joachim</creatorcontrib><creatorcontrib>Spengler, Ulrich</creatorcontrib><creatorcontrib>Gruengreiff, Kurt</creatorcontrib><creatorcontrib>Kaeser, Thomas</creatorcontrib><creatorcontrib>Schuchmann, Marcus</creatorcontrib><creatorcontrib>Bergk, Alexandra</creatorcontrib><creatorcontrib>Forestier, Nicole</creatorcontrib><creatorcontrib>Deterding, Katja</creatorcontrib><creatorcontrib>Manns, Michael P</creatorcontrib><creatorcontrib>Trautwein, Christian</creatorcontrib><creatorcontrib>Hep-Net B/C Co-infection Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Potthoff, Andrej</au><au>Wedemeyer, Heiner</au><au>Boecher, Wulf O</au><au>Berg, Thomas</au><au>Zeuzem, Stefan</au><au>Arnold, Joachim</au><au>Spengler, Ulrich</au><au>Gruengreiff, Kurt</au><au>Kaeser, Thomas</au><au>Schuchmann, Marcus</au><au>Bergk, Alexandra</au><au>Forestier, Nicole</au><au>Deterding, Katja</au><au>Manns, Michael P</au><au>Trautwein, Christian</au><aucorp>Hep-Net B/C Co-infection Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2008-11</date><risdate>2008</risdate><volume>49</volume><issue>5</issue><spage>688</spage><pages>688-</pages><issn>0168-8278</issn><abstract>The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown.
Nineteen patients with chronic HBV/HCV co-infection (HBsAg and HCV-RNA positive; 10 HCV-genotype 1; 9 HCV-genotype 2 or 3) were included in this prospective multicenter pilot study. Baseline HBV-DNA was negative in 13 individuals. All patients received weight-adjusted PEG-IFN-alpha2b and ribavirin for 48 weeks.
In the intent-to-treat analysis, a biochemical and an HCV-RNA response were observed in 12 and 14 patients, respectively (63% and 74%). At the end of the treatment as well as at the end of the follow-up the HCV-RNA response was 93% (14/15) in patients adherent to therapy (86% in genotype 1 and 100% in genotypes 2 and 3 infection). Two of the five initially HBV-DNA positive patients with follow-up available were HBV-DNA negative at follow-up week 24. In contrast, HBV-DNA became detectable after the clearance of HCV in four initially HBV-DNA negative patients.
Combination therapy with PEG-IFN-a2b and ribavirin is highly effective in inducing a virological response concerning HCV in patients with HBV/HCV co-infection. However, HBV replication may increase after the clearance of HCV and thus close monitoring for both the viruses is recommended even in patients with initially undetectable HBV-DNA.</abstract><cop>Netherlands</cop><pmid>18490077</pmid><doi>10.1016/j.jhep.2008.03.028</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-8278 |
ispartof | Journal of hepatology, 2008-11, Vol.49 (5), p.688 |
issn | 0168-8278 |
language | eng |
recordid | cdi_pubmed_primary_18490077 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Adult Aged Antiviral Agents - administration & dosage Antiviral Agents - adverse effects DNA, Viral - blood Female Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Male Middle Aged Polyethylene Glycols Prospective Studies Recombinant Proteins Ribavirin - administration & dosage Ribavirin - adverse effects RNA, Viral - blood |
title | The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T13%3A40%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20HEP-NET%20B/C%20co-infection%20trial:%20A%20prospective%20multicenter%20study%20to%20investigate%20the%20efficacy%20of%20pegylated%20interferon-alpha2b%20and%20ribavirin%20in%20patients%20with%20HBV/HCV%20co-infection&rft.jtitle=Journal%20of%20hepatology&rft.au=Potthoff,%20Andrej&rft.aucorp=Hep-Net%20B/C%20Co-infection%20Study%20Group&rft.date=2008-11&rft.volume=49&rft.issue=5&rft.spage=688&rft.pages=688-&rft.issn=0168-8278&rft_id=info:doi/10.1016/j.jhep.2008.03.028&rft_dat=%3Cpubmed%3E18490077%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18490077&rfr_iscdi=true |